Show simple item record

dc.contributor.authorHeywood, Jamesen
dc.contributor.authorEvangelou, Marinaen
dc.contributor.authorGoymer, Donnaen
dc.contributor.authorKennet, Janeen
dc.contributor.authorAnselmiova, Katerinaen
dc.contributor.authorGuy, Catherineen
dc.contributor.authorO'Brien, Crionaen
dc.contributor.authorNutland, Sarahen
dc.contributor.authorBrown, Judyen
dc.contributor.authorWalker, Neil Men
dc.contributor.authorTodd, Johnen
dc.contributor.authorWaldron-Lynch, Franken
dc.date.accessioned2015-10-07T13:26:05Z
dc.date.available2015-10-07T13:26:05Z
dc.date.issued2015-03-11en
dc.identifier.citationTrials 2015, 16(86), doi: 10.1186/s13063-015-0583-7en
dc.identifier.issn1745-6215
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/251349
dc.description.abstractBackground: A barrier to the successful development of new disease treatments is the timely recruitment of participants to experimental medicine studies that are primarily designed to investigate biological mechanisms rather than evaluate clinical efficacy. The aim of this study was to analyse the performance of three recruitment sources and the effect of publicity events during the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D). Methods: The final study outcome, demography, disease duration, residence and the effect of publicity events on the performance of three recruitment sources (clinics, type 1 diabetes (T1D) disease register and the internet) were analysed from a bespoke DILT1D recruitment database. For the internet source, the origin of website hits in relation to publicity events was also evaluated. Results: A total of 735 potentially eligible participants were approached to identify the final 45 DILT1D participants. A total of 477 (64%) were identified via the disease register, but only 59 (12%) responded to contact. A total of 317 individuals registered with the DILT1D study team. Self-referral via the study website generated 170 (54%) registered individuals and was the most popular and successful source, with 88 (28%) sourced from diabetes clinics and 59 (19%) from the disease register. Of those with known T1D duration (N = 272), the internet and clinics sources identified a larger number (57, 21%) of newly diagnosed T1D (<100 days post-diagnosis) compared to the register (1, 0.4%). The internet extended the geographical reach of the study, enabling both national and international participation. Targeted website posts and promotional events from organisations supporting T1D research and treatment during the trial were essential to the success of the internet recruitment strategy. Conclusions: Analysis of the DILT1D study recruitment outcomes illustrates the utility of an active internet recruitment strategy, supported by patient groups and charities, funding agencies and sponsors, in successfully conducting an early phase study in T1D. This recruitment strategy should now be evaluated in late-stage trials to develop treatments for T1D and other diseases.
dc.description.sponsorshipThis work is funded by the JDRF (9-2011-253), the Wellcome Trust (091157) and the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre. The research leading to these results has received funding from the European Union’s Seventh Framework Programme (FP7/2007-2013) under grant agreement number 241447 (NAIMIT). The Cambridge Institute for Medical Research (CIMR) is in receipt of a Wellcome Trust Strategic Award (100140).
dc.languageEnglishen
dc.language.isoenen
dc.publisherBioMed Central
dc.rightsAttribution 2.0 UK: England & Wales*
dc.rights.urihttp://creativecommons.org/licenses/by/2.0/uk/*
dc.subjectType 1 diabetesen
dc.subjectInterleukin-2en
dc.subjectDisease registeren
dc.subjectInterneten
dc.subjectRecruitmenten
dc.titleEffective recruitment of participants to a phase I study using the internet and publicity releases through charities and patient organisations: analysis of the Adaptive study of IL-2 dose on regulatory T cells in type 1 diabetes (DILT1D)en
dc.typeArticle
dc.description.versionThis is the final version of the article. It first appeared from BMC via http://dx.doi.org/10.1186/s13063-015-0583-7en
prism.publicationDate2015en
prism.publicationNameTrialsen
prism.volume16en
dc.rioxxterms.funderNIHR
dc.rioxxterms.funderWellcome Trust
dc.rioxxterms.funderERC
dc.rioxxterms.projectid091157
dc.rioxxterms.projectid100140
rioxxterms.versionofrecord10.1186/s13063-015-0583-7en
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserveden
rioxxterms.licenseref.startdate2015-03-11en
dc.contributor.orcidWaldron-Lynch, Frank [0000-0002-0597-4328]
dc.identifier.eissn1745-6215
rioxxterms.typeJournal Article/Reviewen
pubs.funder-project-idWellcome Trust (100140/Z/12/Z)
pubs.funder-project-idWellcome Trust (091157/Z/10/B)


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 2.0 UK: England & Wales
Except where otherwise noted, this item's licence is described as Attribution 2.0 UK: England & Wales